시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 계절성 인플루엔자 시장 보고서(2025년)
Seasonal Influenza Global Market Report 2025
상품코드 : 1720892
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,301,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,108,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,914,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

계절성 인플루엔자 시장 규모는 향후 수년간 급성장이 전망될 예정입니다. 경구용 약물 용액에 대한 수요 증가, 연구 개발 활동 확대, 백신 접종률 증가, 스케어 인프라의 개선, 소매 약국 수요 증가에 기인한다고 생각됩니다. 주요 동향으로는 치료 옵션의 진보, 기술 혁신, 백신 개발의 진전, mRNA 기술의 채용, 모니터링과 진단을 위한 디지털 헬스 솔루션의 통합 등을 들 수 있습니다.

호흡기 감염의 유병률 증가는 향후 몇 년 동안 계절성 인플루엔자 시장의 성장을 가속할 것으로 예측됩니다. 대기오염, 기후 변화, 면역반응의 저하, 혼잡한 장소나 환기의 나쁜 장소에서의 바이러스 감염의 용이성 등, 몇몇 요인이 이러한 감염증의 유병률 상승에 기여하고 있습니다. 계절성 인플루엔자 치료는 인플루엔자 바이러스를 표적으로 삼아 루스를 표적으로 하고, 2차 감염으로 이어질 가능성이 있는 증상을 관리하는 것으로, 호흡기 감염증의 예방이나 중증도의 경감에 중요한 역할을 합니다. 2022년 4,380건에서 2023년 4,850건으로 증가한 것으로 나타났습니다. 그 결과 호흡기 감염의 이환율 상승이 계절성 인플루엔자 시장의 확대를 촉진할 것으로 예측됩니다.

계절성 인플루엔자 시장의 주요 기업은 여러 바이러스 균주를 표적으로 함으로써 면역력을 높이고, 효능을 향상시키고, 빈번한 백신 접종의 필요성을 감소시키는 혼합 백신 등의 혁신을 통해 치료 옵션을 진화시키고 있습니다. 혼합 백신은 한 번의 주사로 여러 질병과 바이러스 균주를 예방할 수 있으므로 예방 접종에 필요한 주사 횟수를 최소화할 수 있습니다. Moderna Inc.는 인플루엔자와 COVID-19를 모두 예방하기 위해 고안된 시험용 혼합 백신인 mRNA-1083의 1/2상 임상시험의 중간 결과가 양호하다는 것을 발표했습니다. 강화, 투여를 간소화하고 개인 및 건강 관리 시스템의 편의성을 향상시키기 위해 개발된 mRNA-1083은 표준 인플루엔자 백신인 Fluarix(50-64 세 대상) 및 Fluzone HD(65-79세 대상)및 Spikevax 부스터에 비해 안전성과 면역원성이 평가되고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Seasonal influenza, commonly known as the flu, is a contagious respiratory infection caused by influenza viruses that circulate worldwide, primarily during specific seasons (typically fall and winter in temperate regions). It spreads through respiratory droplets when an infected person coughs, sneezes, or talks. Seasonal influenza causes widespread illness and can lead to severe complications, particularly in vulnerable populations such as the elderly and individuals with weakened immune systems.

The primary types of seasonal influenza include influenza A, B, C, and D viruses. Influenza A virus is a subtype that infects humans and various animals, often responsible for seasonal flu outbreaks and pandemics. Treatments are administered through different routes, including parenteral, oral, and other methods. These treatments are distributed through various channels, such as hospitals, government and institutional supply, pharmacies, and online platforms. Treatment options include antivirals, neuraminidase inhibitors, vaccinations, and other therapeutic approaches.

The seasonal influenza market research report is one of a series of new reports from The Business Research Company that provides seasonal influenza market statistics, including the seasonal influenza industry global market size, regional shares, competitors with the seasonal influenza market share, detailed seasonal influenza market segments, market trends, and opportunities, and any further data you may need to thrive in the seasonal influenza industry. This seasonal influenza market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The seasonal influenza market size has grown rapidly in recent years. It will grow from $8.41 billion in 2024 to $9.88 billion in 2025 at a compound annual growth rate (CAGR) of 17.4%. The growth in the historic period can be attributed to the rising prevalence of influenza, the increasing elderly population, the growing prevalence of infectious and chronic diseases, the rising burden of influenza-related illness, and the surge in respiratory infections.

The seasonal influenza market size is expected to see rapid growth in the next few years. It will grow to $18.55 billion in 2029 at a compound annual growth rate (CAGR) of 17.1%. The growth in the forecast period can be attributed to the increasing demand for oral drug solutions, expanding research and development activities, rising vaccination rates, improving healthcare infrastructure, and the growing demand for retail pharmacies. Major trends include advancements in treatment options, technological innovations, progress in vaccine development, the adoption of mRNA technology, and the integration of digital health solutions for monitoring and diagnosis.

The rising prevalence of respiratory infections is expected to drive the growth of the seasonal influenza market in the coming years. Respiratory infections, caused by viruses or bacteria, affect the respiratory system, including the sinuses, throat, airways, and lungs. Several factors contribute to the increasing prevalence of these infections, including air pollution, climate changes, weakened immune responses, and the ease of viral transmission in crowded or poorly ventilated areas. Seasonal influenza treatments play a crucial role in preventing or reducing the severity of respiratory infections by targeting the influenza virus and managing symptoms that may lead to secondary infections. For example, in October 2024, the UK Health Security Agency reported a 10.7% year-over-year increase in tuberculosis (TB) cases in England, rising from 4,380 cases in 2022 to 4,850 cases in 2023. As a result, the rising incidence of respiratory infections is expected to drive the expansion of the seasonal influenza market.

Leading companies in the seasonal influenza market are advancing treatment options through innovations such as combination vaccines, which enhance immunity by targeting multiple strains of the virus, improving effectiveness, and reducing the need for frequent vaccinations. Combination vaccines offer protection against multiple diseases or viral strains with a single injection, minimizing the number of shots required for immunization. For instance, in October 2023, Moderna, Inc., a US-based biotechnology company, announced positive interim Phase 1/2 trial results for mRNA-1083, an investigational combination vaccine designed to protect against both influenza and COVID-19. Developed to enhance compliance, streamline administration, and improve convenience for individuals and healthcare systems, mRNA-1083 is being evaluated for safety and immunogenicity in comparison to standard flu vaccines Fluarix (for individuals aged 50-64) and Fluzone HD (for individuals aged 65-79), as well as against the Spikevax booster.

In February 2023, Clover Biopharmaceuticals Ltd., a China-based commercial-stage biotechnology company, partnered with Adimmune Corporation to distribute AdimFlu-S (QIS), the only imported quadrivalent seasonal influenza vaccine approved for individuals aged three and older in mainland China. Adimmune Corporation is a Taiwan-based company specializing in vaccine development and production.

Major players in the seasonal influenza market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Sanofi S.A., AstraZeneca PLC, Novartis International AG, GlaxoSmithKline plc, Merck KGaA, Moderna Inc., Boehringer Ingelheim International GmbH, Sinovac Biotech Ltd., Daiichi Sankyo Company Limited, CSL Limited, Genentech Inc., Shionogi & Co. Ltd., Emergent BioSolutions Inc., Novavax Inc., BioCryst Pharmaceuticals Inc., Bharat Biotech International Limited, Vaxart Inc., Inovio Pharmaceuticals Inc., SK bioscience Co. Ltd., Mitsubishi Tanabe Pharma Corporation, FluGen Inc., Altimmune Inc.

North America was the largest region in the seasonal influenza market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in seasonal influenza report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the seasonal influenza market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The seasonal influenza market consists of revenues earned by entities by provide services such flu vaccination services, specialized care for high-risk populations, telemedicine services, and proactive treatment. The market value includes the value of related goods sold by the service provider or included within the service offering. The seasonal influenza market consists of sales of medications, diagnostic kits, preventive and supportive products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Seasonal Influenza Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on seasonal influenza market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for seasonal influenza ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The seasonal influenza market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Seasonal Influenza Market Characteristics

3. Seasonal Influenza Market Trends And Strategies

4. Seasonal Influenza Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Seasonal Influenza Growth Analysis And Strategic Analysis Framework

6. Seasonal Influenza Market Segmentation

7. Seasonal Influenza Market Regional And Country Analysis

8. Asia-Pacific Seasonal Influenza Market

9. China Seasonal Influenza Market

10. India Seasonal Influenza Market

11. Japan Seasonal Influenza Market

12. Australia Seasonal Influenza Market

13. Indonesia Seasonal Influenza Market

14. South Korea Seasonal Influenza Market

15. Western Europe Seasonal Influenza Market

16. UK Seasonal Influenza Market

17. Germany Seasonal Influenza Market

18. France Seasonal Influenza Market

19. Italy Seasonal Influenza Market

20. Spain Seasonal Influenza Market

21. Eastern Europe Seasonal Influenza Market

22. Russia Seasonal Influenza Market

23. North America Seasonal Influenza Market

24. USA Seasonal Influenza Market

25. Canada Seasonal Influenza Market

26. South America Seasonal Influenza Market

27. Brazil Seasonal Influenza Market

28. Middle East Seasonal Influenza Market

29. Africa Seasonal Influenza Market

30. Seasonal Influenza Market Competitive Landscape And Company Profiles

31. Seasonal Influenza Market Other Major And Innovative Companies

32. Global Seasonal Influenza Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Seasonal Influenza Market

34. Recent Developments In The Seasonal Influenza Market

35. Seasonal Influenza Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기